Torrent Pharmaceuticals Limited (TORNTPHARM) — Corporate Action | 20 May 2025(2 announcements)

{ "summary": "Torrent Pharmaceuticals reported a 15% YoY revenue jump to ₹11,516 crores for FY2025, driven by 8% growth in Q4 to ₹2,959 crores, with PAT rising 11% to ₹498 crores (16.8% margin). The company proposed a final dividend of ₹6 per share (120% payout) and recommended appointing Aman Mehta as Managing Director effective August 1, 2025. Key risks include currency volatility in Brazil and regulatory compliance in international markets.", "extractedFields": { "keyEvent": "Aman Mehta appointed Managing Director effective August 1, 2025", "whatChanged": "Revenue grew 15% YoY to ₹11,516 crores; PAT increased 11% to ₹498 crores", "forwardGuidance": "August 1, 2025", "investorTakeaway": "Strong revenue and profit growth with a proposed dividend increase signals financial resilience and management confidence", "dividend": { "finalDividendPerShare": 6, "payoutPercentage": 120, "equityShareFaceValue": 5, "interimDividendPreviouslyPaidPerShare": 26, "dividendPaymentDate": "on or around 4 August 2025" }, "financialResults": { "auditOpinion": "unmodified", "auditFirm": "BS R & Co. LLP", "financialYearEnd": "31 March 2025", "revenueFromOperations": { "netSales": { "currentYear": 2385, "previousYear": 2094 }, "totalRevenueFromOperations": { "currentYear": 2433, "previousYear": 2143 } }, "totalIncome": { "currentYear": 2448, "previousYear": 2219 }, "expenses": { "costOfMaterialsConsumed": { "currentYear": 402, "previousYear": 409 }, "purchasesOfStockInTrade": { "currentYear": 205, "previousYear": 168 }, "employeeBenefitsExpense": { "currentYear": 416, "previousYear": 353 }, "financeCost": { "currentYear": 10, "previousYear": 11 }, "exceptionalItems": { "currentYear": 0, "previousYear": 0 }, "taxExpense": { "currentYear": 276, "previousYear": 236 } }, "totalIncome": { "currentYear": 2448, "previousYear": 2219 }, "profitBeforeTax": { "currentYear": 1872, "previousYear": 1683 }, "profitAfterTax": { "currentYear": 1888, "previousYear": 1697 }, "totalComprehensiveIncome": { "currentYear": 1847, "previousYear": 1606 }, "totalAssets": { "currentYear": 14990, "previousYear": 13877 }, "totalEquity": { "currentYear": 7591, "previousYear": 6925 }, "totalLiabilities": { "currentYear": 7399, "previousYear": 6952 }, "debtEquityRatio": 0.34, "deferredTaxReversal": 151, "taxRegimeTransition": "Transition to new tax regime from FY 2025-26", "auditOpinion": "Unqualified", "auditFirm": "BS R & Co. LLP", "exchange": "NSE", "filingDate": "2025-05-20", "fiscalYearEnd": "31-Mar-2025", "auditedFigures": true, "segment": "Generic Formulation Business", "creditRatings": { "ICRA": "AA+(Stable)", "IndiaRating": "IND AA+ (Stable)" }, "outstandingQualifiedBorrowings": 1605, "highestCreditRatingAgency": "ICRA", "debtSecurityRating": "AA+ (Long Term)", "shortTermRating": "Al+" }, "auditReport": { "auditorFirm": "BS R & Co. LLP", "auditPeriodEnd": "31 March 2025", "auditorOpinion": "Unqualified", "consolidatedNetProfit": 47.08, "consolidatedRevenue": 3045.69, "consolidatedTotalAssets": 3847.88, "currency": "INR", "currencyUnit": "crores", "subsidiariesIncluded": 16, "regulatoryCompliance": [ "SEBI Listing Obligations and Disclosure Requirements Regulations, 2015", "Indian Accounting Standards", "Regulation 33 and Regulation 52(4) read with Regulation 63" ], "auditStandards": [ "Standards on Auditing (SAs) under section 143(10) of the Companies Act, 2013" ], "goingConcernAssessment": "No material uncertainty identified", "reportDate": "20 May 2025", "reportLocation": "Mumbai" }, "appointment": { "name": "Aman Mehta", "effectiveDate": "2025-08-01", "term": "5 years", "position": "Managing Director and Whole-time Key Managerial Personnel" }, "financials": { "q4Revenue": 2959, "q4RevenueYoY": 8, "grossProfitMargin": 75.3, "opEBITDA": 964, "opEBITDAMargin": 32.6, "opEBITDAYoY": 9,

Torrent Pharmaceuticals announced that Friday, 20 June 2025 will be the record date for determining shareholders entitled to receive a final dividend for the fiscal year 2024-25, contingent on declaration by the board.